Drug Profile
Bevacizumab biosimilar - Pfizer
Alternative Names: PF-06439535; PF-6439535; ZIRABEVLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Renal cancer
- Registered Breast cancer
Most Recent Events
- 04 Oct 2021 Discontinued - Phase-III for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT04325698)
- 29 Jul 2021 Pfizer terminates a phase III trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy, Combination therapy) in China (IV), as the company decided to halt its biosimilars programs (NCT04325698)
- 27 Apr 2021 Pfizer withdraws a phase I pharmacokinetic trial for Healthy volunteers in China before enrolment after comprehensive review of the biosimilars market and the company's global manufacturing network (IV) (NCT04126044)